Slides
Page 1
Results Q1FY27 Aug 06 , 2026 Emcure
Page 2
241 241 241 212 57 39 155 159 155 245 138 127 1 73 125 252 232 230 Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute “forward-looking statements.” These statements are based on Emcure Pharmaceuticals Limited’s current expectations, assumptions, and projections about future events. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such statements may include, but are not limited to, references to Emcure’s business strategy, expansion plans, R&D pipeline, regulatory developments, financial performance, operational efficiencies, market conditions, and other future events. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “may,” “will,” “should,” and similar expressions are intended to identify forward-looking statements. These risks and uncertainties include regulatory changes, competitive pressures, technology changes, supply chain challenges, currency fluctuations, ability to obtain or maintain approvals, product commercialization timelines, and other risks inherent to the pharmaceutical industry. This presentation is for general information only and does not constitute an offer, invitation, solicitation, or recommendation to buy, sell, or subscribe to any securities of Emcure Pharmaceuticals Limited. Product information, including molecules under development or awaiting approval, is for representation purposes only. Availability of products may vary by geography depending on regulatory approvals and patent status. This presentation is not intended to provide medical advice. The Company does not undertake to update or revise any forward-looking statements based on new information or future events. Disclaimer
Page 3
241 241 241 212 57 39 155 159 155 245 138 127 1 73 125 252 232 230 Q1 FY27 – Corporate Updates Mr. Satish Mehta to take over as Chairman, in addition to his existing role as Managing Director & CEO (post the conclusion of the upcoming AGM) These steps strengthen the institutional depth required to deliver our five-year plan and create enduring value over the long term 3 Gennova Biopharmaceuticals, now a wholly-owned subsidiary ▪ Mr. Samit Mehta to lead as CEO ▪ Will continue to anchor the Group's biologics and biosimilars capabilities ▪ Will complement Emcure's broader R&D and pipeline priorities Mr. Samit Mehta appointed COO of Emcure Pharmaceuticals ▪ Gets broader oversight of the Group’s R&D, operations and licensing activities. ▪ The elevation strengthens Emcure’s leadership and reinforces continuity in promoter-family stewardship
Page 4
241 241 241 212 57 39 155 159 155 245 138 127 1 73 125 252 232 230 Q1 FY27 - Key Financial Snapshot 1 Revenue / Growth 25,804 / 22.8% Revenue (INR Mn) / YoY growth EBITDA / Margin 5,080 / 19.7% EBITDA (INR Mn) / Margin PAT / Margin 2,925 / 11.3% PAT (INR Mn) / Margin 50 bps 110 bps ▪ Strong all-round performance with increased contribution from the International business (58%) ▪ International Business revenue up 34.2% YoY with strong growth across Europe, RoW and Canada ▪ Domestic revenue growth at 10.2%, reflecting a resilient performance ▪ Productivity gains and operating leverage help improve EBITDA margin by 50 bps ▪ PAT margin up 110 bps, at 11.3% - underline the strength of the quarter’s operating performance. Key Highlights – Q1FY27 Segment Revenue Mix – Q1FY27 4 42% India 20% RoW 21% EU 17% CA Domestic — 42% International — 58%
Page 5
241 241 241 212 57 39 155 159 155 245 138 127 1 73 125 252 232 230 Q1FY27 – Other Financial Data Points R&D (INR Mn) 2,875 3,835 730 904 FY25 FY26 Q1FY26 Q1FY27 3,763 4,342 948 1,168 FY25 FY26 Q1FY26 Q1FY27 R&D as % of Revenue 4,883 10,538 11,026 31-Mar-2025 31-Mar-2026 30-Jun-2026 Net debt to TTM2 EBITDA (x) 0.3 0.6 RoCE1 CAPEX (INR Mn) Net debt (INR Mn) 3.6% 3.5% 22.0% 23.7% 23.4% 31-Mar-2025 31-Mar-2026 30-Jun-2026 4.2% 3.5% 0.7 5 1RoCE refers to Return on Capital Employed, and is calculated by dividing EBIT for a given year by Capital Employed (i.e., tot al equity plus Net Debt) as of the end of that year; 2TTM: Trailing twelve months
Page 6
241 241 241 212 57 39 155 159 155 245 138 127 1 73 125 252 232 230 Q1 FY27 – Domestic Business Performance ▪ Performance in line with expectations, supported by normalized Zuventus performance. ▪ Growth across CNS, women’s health franchise and cardio- metabolics range led by key brands like Tenectase, Orofer XT , Orofer FCM, Metpure, etc. and supported by the Sanofi OAD and Roche portfolio ▪ Improved share of chronic segment ▪ Continue to build Poviztra® uptake; recent MASH1 indication to help expand beyond traditional cardio-metabolics franchise ▪ Continued productivity enhancement reflected in increasing PCPM Domestic (INR Mn) 1MASH– Metabolic dysfunction-associated steatohepatitis Expect continued growth over the full year as our strengthened team and portfolio gain traction 6 Key Highlights 36,597 40,270 9,935 10,953 FY25 FY26 Q1FY26 Q1FY27
Page 7
241 241 241 212 57 39 155 159 155 245 138 127 1 73 125 252 232 230 Q1 FY27 – International Business Performance 14,738 18,498 4,042 5,367 FY25 FY26 Q1FY26 Q1FY27 12,520 14,869 3,425 4,266 FY25 FY26 Q1FY26 Q1FY27 Europe (INR Mn) Canada (INR Mn) ▪ Strong EU and steady U.K. performance led by continued base business execution ▪ Liposomal Amphotericin B contribution continues to grow ▪ Product pipeline provides continued visibility for sustained growth over the medium term ▪ Healthy growth through market share gains and new launches ▪ Growth balanced in both Quebec and rest of the Canada markets ▪ Received one product approval and launched two new products 1ARV – Anti retroviral , 2 PrEP - Pre-exposure prophylaxis A well diversified international platform driven by sustained business performance across both the base business and new business opportunities 7 ARV1 ▪ Strong orderbook led performance ▪ Signed a royalty-free, non-exclusive voluntary licensing agreement with MSD for alimatravir, a once-monthly oral PrEP² candidate, currently in late-stage development Non-ARV1 ▪ Scaling up of in-house developed portfolio across key markets ▪ 15+ products approved across Asia, Africa and LATAM in Q1 FY27; expanded into 3 new territories RoW (INR Mn) 15,105 18,399 3,603 5,218 FY25 FY26 Q1FY26 Q1FY27
Page 8
241 241 241 212 57 39 155 159 155 245 138 127 1 73 125 252 232 230 P&L Summary | Q1 FY27 INR Mn except % Q1 FY27 Q1 FY26 YoY % Q4 FY26 QoQ % FY26 Revenue from Operations 25,804 21,005 22.8% 24,697 4.5% 92,035 Domestic 10,953 9,935 10.2% 9,772 12.1% 40,270 International 14,851 11,070 34.2% 14,925 -0.5% 51,766 RoW 5,218 3,603 44.8% 5,557 -6.1% 18,399 EU 5,367 4,042 32.8% 5,376 -0.2% 18,498 CA 4,266 3,425 24.6% 3,992 6.9% 14,869 Gross Profit 15,073 12,985 16.1% 14,666 2.8% 55,465 Gross Profit Margin 58.4% 61.8% 340bps 59.4% 100bps 60.3% EBITDA 5,080 4,039 25.8% 4,855 4.6% 17,886 EBITDA Margin 19.7% 19.2% 50bps 19.7% - 19.4% Profit Before Tax (PBT) 3,935 2,908 35.3% 3,412 15.3% 12,871 Effective Tax Rate (%) 25.7% 26.1% 28.6% 26.9% Profit After Tax (PAT) 2,925 2,148 36.2% 2,437 20.0% 9,413 PAT Margin 11.3% 10.2% 110bps 9.9% 140bps 10.2% Adjusted Profit After Tax (PAT)1 2,909 2,174 33.8% 2,789 4.3% 10,075 Adjusted PAT Margin 11.3% 10.3% 100bps 11.3% - 10.9% 8 1. Exceptional item, impact of labour code, Changes in fair value of contingent consideration
Page 9
241 241 241 212 57 39 155 159 155 245 138 127 1 73 125 252 232 230 For further information / institutional investor queries Contact: Saurabh Paliwal Email: Investor.Relations@emcure.com Registered Office Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune 411 057, Maharashtra, India Website www.emcure.com Q1 FY27 CONFERENCE CALL DET AILS Date: Thursday, August 6, 2026 Time: 04:00 pm IST To Register: Click here to register